The Italian government's decision not to increase the pharmaceutical spending ceiling in its latest budget maneuver has been met with disappointment from Marcello Cattani, president of Farmindustria.
Cattani expressed concern over the implications of this decision, particularly the increased financial burden on pharmaceutical companies due to the payback system. He emphasized the need for a reassessment of the spending ceiling to ensure the sustainability of the pharmaceutical industry in Italy, which plays a crucial role in healthcare and innovation.
Cattani's remarks came after meetings with key ministers, including Ministers Giorgetti and Schillaci. While he acknowledged the government's commitment to the innovative drugs fund, he criticized the lack of action regarding the spending ceiling. The president of Farmindustria pointed out that the absence of an increase could hinder the production of essential life-saving drugs, potentially leading to shortages in the market. He called for immediate repeal of Article 57, which he believes unfairly reduces pharmaceutical companies' margins in favor of distribution entities.
The viability of the pharmaceutical sector in Italy is under scrutiny as Cattani raised concerns about the sustainability of drug production. He argued that the proposed measures could exacerbate existing challenges, making it increasingly difficult for companies to operate effectively. The president of Farmindustria stressed that the industry must not bear the financial burden of distribution costs, advocating for a model that supports competitiveness without compromising the margins of pharmaceutical companies.
Cattani's comments reflect a broader concern within the industry regarding the government's approach to pharmaceutical legislation. He urged the government to prioritize the interests of the pharmaceutical sector, which he described as a vital engine for competitiveness in both Italy and the European Union. Cattani pointed out that Italy is a leader in pharmaceutical production, and any measures that undermine this position could have far-reaching consequences for the economy and healthcare system.
In light of the current challenges, Cattani called for a comprehensive industrial strategy that supports the life sciences sector. He emphasized the importance of protecting patents and investing in research and development to foster innovation. Cattani referenced the competitive landscape in Europe, particularly in relation to the United States, and urged for swift action to enhance the pharmaceutical industry's position on the global stage.
The president of Farmindustria also highlighted the need for a long-term vision to address drug shortages. He proposed a strategy that would bring the production of active ingredients back to Europe, ensuring that all drugs receive the appropriate value and access. Cattani's vision aligns with the sentiments expressed by former leaders, including Mario Draghi and Enrico Letta, who warned against ideological approaches that could undermine the pharmaceutical sector's growth and sustainability.
As the Italian government navigates its budgetary decisions, the pharmaceutical industry remains vigilant, advocating for policies that support innovation, competitiveness, and the overall health of the nation. The ongoing dialogue between industry leaders and government officials will be crucial in shaping the future of pharmaceutical spending and ensuring that Italy maintains its status as a leader in the global pharmaceutical landscape.